Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2019-03-08 Director's Dealing
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2019-03-08 English
8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 4, 2019, by Pacira Pharmaceuticals, Inc. The content focuses on the announcement of a material definitive agreement, specifically a merger agreement with MyoScience, Inc. It details the terms of the merger, consideration, milestone payments, and conditions for closing. There is also mention of a press release related to the acquisition and a corporate name change. The document includes the merger agreement as an exhibit and a press release. This type of filing is a current report announcing a significant corporate transaction, specifically a merger/acquisition event. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category 'M&A Activity' (Code: TAR). The document is not a full merger proxy statement or tender offer filing (which would be under 'MA'), but rather an 8-K current report announcing the merger agreement and related events. Therefore, the appropriate classification is 'TAR' with high confidence.
2019-03-05 English
10-K - PCRX - 12.31.2018
Annual Report FY 2018
2019-02-28 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Pacira Pharmaceuticals, Inc. It specifically includes an Item 2.02 titled 'Results of Operations and Financial Condition' and references an attached Exhibit 99.1 which is an Earnings Press Release dated February 28, 2019. The text states that the press release announces results for the fourth quarter and full year ended December 31, 2018. The document itself is a short filing (3322 characters) and primarily serves to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, initial announcements of quarterly or periodical financial results with key highlights only are classified as Earnings Release (ER). Therefore, this document is best classified as an Earnings Release (ER).
2019-02-28 English
SC 13G/A
Major Shareholding Notification
2019-02-14 English
SCHEDULE 13G
Major Shareholding Notification
2019-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.